The world’s first mixture seasonal influenza and COVID-19 vaccine, Moderna’s mCombriax, has obtained advertising authorization from the European Fee, following a optimistic evaluation from the European Medicines Company’s Committee for Medicinal Merchandise for Human Use.
“By combining safety in opposition to two important respiratory viruses in a single dose, our vaccine goals to simplify immunization for adults, significantly these at excessive threat,” mentioned Moderna CEO Stephane Bancel, MBA, in a press launch. “mCOMBRIAX provides an necessary new choice for Europeans, whereas additionally aiming to strengthen the resilience of healthcare techniques throughout Europe.”
Shot carried out properly in older adults
In keeping with the corporate, mCombriax was primarily based on the medical improvement of mNexspike, Moderna’s COVID-19 vaccine, and mRNA-1010, Moderna’s investigational seasonal influenza vaccine, which has been accepted for evaluation within the European Union (EU), United States, Canada, and Australia.
The vaccine carried out properly in a section 3 trial, the place a single dose elicited statistically important larger immune responses in opposition to three influenza virus strains (A/H1N1, A/H3N2, and B/Victoria) and in opposition to SARS-CoV-2 in adults 50 to 64 years and 65 years and older.
The advertising authorization is legitimate in all 27 EU member states, in addition to Iceland, Liechtenstein, and Norway. No main security considerations or opposed occasions had been seen within the section 3 trial.
